author-photo

Anja Binckebanck

Goethe University Frankfurt

19

Papers

1316

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

(Ph+ ALL) outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia Early molecular response to posttransplantation imatinib determines

2013
Show All
- Source
- Cite
- Save
Citations (0)
ALL) treated with imatinib + Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph Early prediction of response in patients with relapsed or refractory

2010
Show All
- Source
- Cite
- Save
Citations (0)
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib

2008 Haematologica
Show All
- Source
- Cite
- Save
Citations (39)
Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)

2006 Blood
Show All
- Source
- Cite
- Save
Citations (297)
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

2005 Blood
Show All
- Source
- Cite
- Save
Citations (183)
Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

2005 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Risk and Prognosis of Central Nervous System Leukemia in Patients with Philadelphia Chromosome-Positive Acute Leukemias Treated with Imatinib Mesylate

2003 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (99)
Efficacy and safety of imatinib mesylate (Glivec™) in combination with interferon- α (IFN- α ) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL)

2003 Leukemia
Show All
- Source
- Cite
- Save
Citations (41)
In de novo Ph+ALL Imatinib, given intermittently or simultaneously with chemotherapy, can effectively reduce the leukemic cell burden but induces molecular remissions in only a subset of patients

2003 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph + /BCR-ABL + ) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)

2003 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (23)